Skip to content
TrialScanner

NCT03624010

Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients

Phase 2CompletedTENXLeadMEDPCollaborator

Registry record

Lead sponsor
Tenax Therapeutics, Inc.
Conditions
Hypertension Pulmonary Secondary Heart Failure; Right Sided Heart Failure With Normal Ejection Fraction; Heart Failure With Normal Ejection Fraction
Primary completion
Apr 25, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03624010 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03624010: Open-Label Rollover Study of... | TrialScanner